|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
ALK inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2014
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Zykadia
|
|
gptkbp:class
|
antineoplastic agent
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
Phase I
second-line treatment
first-line treatment
NC T02259523
NC T01828112
NC T02098495
NC T02432826
NC T02737501
|
|
gptkbp:contraindication
|
liver disease
hypersensitivity to ceritinib
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zykadia
|
|
gptkbp:ingredients
|
gptkb:ceritinib
|
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:invention
|
2029
patented
|
|
gptkbp:is_monitored_by
|
cardiac function
electrolytes
liver function tests
|
|
gptkbp:is_used_for
|
treatment of non-small cell lung cancer
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Novartis
|
|
gptkbp:marketed_as
|
gptkb:ceritinib
|
|
gptkbp:packaging
|
gptkb:beer
|
|
gptkbp:population
|
ALK-positive non-small cell lung cancer patients
|
|
gptkbp:previous_name
|
gptkb:ceritinib
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:requires
|
available online
|
|
gptkbp:research_focus
|
gptkb:healthcare_organization
targeted therapy
ALK rearrangements
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
fatigue
nausea
abdominal pain
vomiting
diarrhea
rash
liver enzyme elevation
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:bfsParent
|
gptkb:Genzyme_Genetics
|
|
gptkbp:bfsLayer
|
5
|